ORAMED PHARMACEUTICALS INC. Earnings Per Share (Basic)
ORAMED PHARMACEUTICALS INC. (ORMP) reported Earnings Per Share (Basic) of $1.90 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2026-06-30 was $1.90, a 493.75% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2026-03-31 was $0.94.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2025-09-30 was $1.16.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for the quarter ending 2025-06-30 was $0.32, a 45.45% increase year-over-year.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for fiscal 2025 was $1.53.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for fiscal 2024 was -$0.48, a 442.86% decline from fiscal 2023.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for fiscal 2023 was $0.14.
- ORAMED PHARMACEUTICALS INC. earnings per share, basic for fiscal 2022 was -$0.94.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 4 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 8 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.90 10-Q · filed 2026-08-10 | $2.85 10-Q · filed 2026-08-10 | ||||||||
| 2026-03-31 | $0.94 10-Q · filed 2026-05-19 | |||||||||
| 2025-12-31 | $1.53 10-K · filed 2026-03-26 | |||||||||
| 2025-09-30 | $1.16 10-Q · filed 2025-11-13 | $1.30 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | $0.32 10-Q · filed 2026-08-10 | $0.14 10-Q · filed 2026-08-10 | ||||||||
| 2025-03-31 | -$0.19 10-Q · filed 2026-05-19 | |||||||||
| 2024-12-31 | -$0.48 10-K · filed 2026-03-26 | |||||||||
| 2024-09-30 | -$0.48 10-Q · filed 2025-11-13 | -$0.22 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | $0.22 10-Q · filed 2025-08-14 | $0.26 10-Q · filed 2025-08-14 | ||||||||
| 2024-03-31 | $0.04 10-Q · filed 2025-05-15 | |||||||||
| 2023-12-31 | $0.14 10-K · filed 2025-03-27 | |||||||||
| 2023-09-30 | -$0.08 10-Q · filed 2024-11-07 | $0.08 10-Q · filed 2023-11-09 | -$0.19 10-Q · filed 2024-11-07 | $0.19 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | -$0.03 10-Q · filed 2024-08-14 | $0.03 10-Q · filed 2023-08-10 | -$0.11 10-Q · filed 2024-08-14 | $0.11 10-Q · filed 2023-08-10 | ||||||
| 2023-03-31 | -$0.08 10-Q · filed 2024-05-09 | $0.08 10-Q · filed 2023-05-11 | -$0.30 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.48 derived: net income ÷ weighted average shares · filed 2024-05-09 | -$0.75 derived: net income ÷ weighted average shares · filed 2024-05-09 | |||||
| 2022-12-31 | -$0.22 derived: net income ÷ weighted average shares · filed 2024-03-06 | $0.31 10-K · filed 2023-03-06 | -$0.40 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$0.67 derived: net income ÷ weighted average shares · filed 2024-03-06 | -$0.94 10-K · filed 2024-03-06 | $0.94 10-K · filed 2023-03-06 | ||||
| 2022-09-30 | $0.18 10-Q · filed 2023-11-09 | -$0.45 derived: net income ÷ weighted average shares · filed 2023-11-09 | $0.72 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | $0.27 10-Q · filed 2023-08-10 | $0.54 10-Q · filed 2023-08-10 | ||||||||
| 2022-03-31 | $0.27 10-Q · filed 2023-05-11 | |||||||||
| 2021-09-30 | $0.21 10-Q · filed 2022-11-10 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-11-10 | $0.54 10-Q · filed 2022-11-10 | |||||||
| 2021-08-31 | $0.78 10-K · filed 2023-03-06 | |||||||||
| 2021-06-30 | $0.12 10-Q · filed 2022-08-10 | $0.32 10-Q · filed 2022-08-10 | ||||||||
| 2021-03-31 | $0.20 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |